Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Latest update on major events announcements of Shanghai and Shenzhen listed companies on the evening of March 8
Shanghai and Shenzhen listed companies released company announcements on the evening of March 8. Here is a summary of important notices.
【Major Events】
Zhongnan Culture: Plans to acquire 57.30% stake in Jiangyin Sulong Thermal Power; stock to resume trading tomorrow
Zhongnan Culture announced that the company plans to purchase a 57.30% stake in Jiangyin Sulong Thermal Power Co., Ltd., held by Jiangyin Electric Power Investment Co., Ltd., through issuing shares and paying cash. It also plans to raise supporting funds from no more than 35 specific investors. The audit and valuation work related to this transaction are not yet complete, and the transaction plan requires further discussion and negotiation. This transaction is expected to constitute a major asset restructuring. After completion, the company’s business layout in the power energy sector will be expanded. Additionally, the company will further leverage its advantages in industrial metal pipe manufacturing, strengthen sales in the power sector, enhance brand awareness, and increase market share of products, further growing its machinery manufacturing segment. The company has applied to the Shenzhen Stock Exchange for the stock to resume trading on March 9, 2026 (Monday).
Huashu Holdings: Company’s carbon emission management, precision machine tool manufacturing, and sales are still in the cultivation stage, with a low proportion
Huashu Holdings issued an abnormal fluctuation announcement stating that the company’s stock price has deviated by more than 20% over three consecutive trading days, indicating abnormal trading fluctuations. The company’s main business is the research, design, production, and sales of electronic information display terminals. The company’s operations are normal, and its main business has not undergone significant changes. Its carbon emission management, precision machine tool manufacturing, and sales businesses are still in the cultivation stage, with a low proportion. Investors are advised to be cautious and invest rationally.
Shandong Molong: Short-term fluctuations in international crude oil prices do not materially benefit the company’s performance
Shandong Molong announced that its stock price has deviated by more than 20% over three consecutive trading days, indicating abnormal trading fluctuations. Since March 2, 2026, the stock has increased by a total of 52.37% over five trading days, indicating market enthusiasm and potential irrational speculation risks. The company’s operations are normal, and short-term fluctuations in international crude oil prices do not provide substantial benefits to its performance. Investors are advised to make rational decisions, invest cautiously, and be aware of trading risks in the secondary market.
【Increases and Reductions in Holdings】
Fumiao Technology: Shareholder Feixiang Co., Ltd. plans to reduce holdings by no more than 2%
Fumiao Technology announced that its shareholder Jiangsu Feixiang Chemical Co., Ltd., holding over 5% of shares, plans to reduce its holdings by no more than 2% of the total share capital through block trading due to operational needs. The reduction will occur within three months after the announcement, from March 31, 2026, to June 30, 2026.
Laplace: Shareholders intend to reduce holdings by no more than 1%
Laplace announced that major shareholders such as Yedong Hengjun, Sanya Hengjia, Rudong Ruiduo, and Rudong Jiada, holding over 5%, plan to reduce their holdings by no more than 4,053,261 shares (less than 1% of total share capital) through centralized bidding due to their own funding needs. The reduction period is within three months after the announcement, starting 15 trading days after the announcement, with prices determined by market conditions.
Hongbai New Materials: Shareholder Xinyu Jinhong plans to reduce holdings by no more than 0.32%
Hongbai New Materials announced that shareholder Xinyu Jinhong Technology Partnership (Limited Partnership), due to funding needs, plans to reduce its holdings by no more than 2.3 million shares (less than 0.32%) through centralized bidding within three months after the disclosure, from March 31, 2026, to June 30, 2026.
【Other】
GreenMe: Signs strategic cooperation agreement with China Enfei to jointly promote key mineral resource development
GreenMe announced that it has signed a strategic cooperation agreement with China Enfei Engineering Technology Co., Ltd., to deepen cooperation in key mineral resource development, green low-carbon efficient utilization, and global deployment. The agreement aims to enhance the global competitiveness of Chinese enterprises, safeguard national strategic security of key mineral resources, promote technological independence, and support high-quality development. The agreement is valid until December 31, 2030.
Haisico: Receives acceptance notice for innovative drug HSK39297 tablets
Haisico announced that its subsidiary Sichuan Haisico Pharmaceutical Co., Ltd. recently received the acceptance notice from the National Medical Products Administration for HSK39297 tablets, used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults. The drug is a self-developed small molecule inhibitor of complement factor B (FB), which inhibits complement amplification by blocking FB activity, thereby suppressing the entire complement pathway. HSK39297 offers significant advantages over eculizumab in improving anemia, reducing transfusion needs, and alleviating fatigue, with long-lasting efficacy. According to China’s new chemical drug registration classification, it is categorized as a Class 1 chemical drug.
Fengshang Culture: Dismisses Vice General Manager Li Yan
Fengshang Culture announced that at its 15th meeting of the 4th Board of Directors on March 7, 2026, the board approved the dismissal of Vice General Manager Li Yan. Based on operational needs and after review by the Nomination Committee, the board decided to dismiss Li Yan from his vice general manager position. His term was scheduled to end on August 1, 2027. The dismissal is effective immediately upon approval, and Li Yan will no longer hold any positions in the company. As of this announcement, Li Yan does not hold any shares in the company and has no unfulfilled commitments.